Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
CP

WKN: A42HWN | ISIN: US23126K3041 | Ticker:
NASDAQ
17.11.26 | 15:30
4,700 US-Dollar
+3,98 % +0,180
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CURANEX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CURANEX PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur CURANEX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCuranex Pharmaceuticals Inc - 10-Q, Quarterly Report-
19.10.Curanex Pharmaceuticals Inc - S-8, Securities to be offered to employees in employee benefit plans3
19.10.Curanex Pharmaceuticals Inc - 8-K, Current Report1
04.09.Curanex Pharmaceuticals Inc - 8-K, Current Report5
CURANEX PHARMACEUTICALS Aktie jetzt für 0€ handeln
17.08.Curanex Pharmaceuticals Inc - 8-K, Current Report1
21.07.Curanex Pharmaceuticals Inc - S-8, Securities to be offered to employees in employee benefit plans1
14.05.Curanex Pharmaceuticals Inc: Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission321Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated...
► Artikel lesen
08.04.Curanex Pharmaceuticals Inc: Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline344Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple critically...
► Artikel lesen
02.04.Curanex Pharmaceuticals Inc: Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development ...483Company expands strategic focus into one of oncology's most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ("Curanex"...
► Artikel lesen
30.03.Curanex Pharmaceuticals Inc: Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission584Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex...
► Artikel lesen
18.03.Curanex Pharmaceuticals Inc: Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission387Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1